187 related articles for article (PubMed ID: 23099060)
1. A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia.
Chengappa KN; Turkin SR; DeSanti S; Bowie CR; Brar JS; Schlicht PJ; Murphy SL; Hetrick ML; Bilder R; Fleet D
Schizophr Res; 2012 Dec; 142(1-3):145-52. PubMed ID: 23099060
[TBL] [Abstract][Full Text] [Related]
2. Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia.
F Egan M; Zhao X; Gottwald R; Harper-Mozley L; Zhang Y; Snavely D; Lines C; Michelson D
Schizophr Res; 2013 May; 146(1-3):224-30. PubMed ID: 23523692
[TBL] [Abstract][Full Text] [Related]
3. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
[TBL] [Abstract][Full Text] [Related]
4. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.
Sumiyoshi T; Park S; Jayathilake K; Roy A; Ertugrul A; Meltzer HY
Schizophr Res; 2007 Sep; 95(1-3):158-68. PubMed ID: 17628435
[TBL] [Abstract][Full Text] [Related]
5. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study.
Fagerlund B; Søholm B; Fink-Jensen A; Lublin H; Glenthøj BY
Clin Neuropharmacol; 2007; 30(1):3-12. PubMed ID: 17272964
[TBL] [Abstract][Full Text] [Related]
6. Cognitive and negative symptoms in schizophrenia with L-Carnosine adjuvant therapy - A randomized double-blind placebo-controlled study.
Tharoor H; Maran S; Chandan AK; Pari M; Rao S; Durairaj J
Pharmacol Res Perspect; 2023 Apr; 11(2):e01074. PubMed ID: 36946070
[TBL] [Abstract][Full Text] [Related]
7. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
8. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
Lee BJ; Lee JG; Kim YH
J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979
[TBL] [Abstract][Full Text] [Related]
9. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
[TBL] [Abstract][Full Text] [Related]
10. Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder.
Chengappa KN; Bowie CR; Schlicht PJ; Fleet D; Brar JS; Jindal R
J Clin Psychiatry; 2013 Nov; 74(11):1076-83. PubMed ID: 24330893
[TBL] [Abstract][Full Text] [Related]
11. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
Akhondzadeh S; Mohammadi N; Noroozian M; Karamghadiri N; Ghoreishi A; Jamshidi AH; Forghani S
Schizophr Res; 2009 Feb; 107(2-3):206-12. PubMed ID: 18789844
[TBL] [Abstract][Full Text] [Related]
12. Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA.
Ritsner MS; Strous RD
J Psychiatr Res; 2010 Jan; 44(2):75-80. PubMed ID: 19665142
[TBL] [Abstract][Full Text] [Related]
13. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation.
Sharma T; Reed C; Aasen I; Kumari V
Schizophr Res; 2006 Jul; 85(1-3):73-83. PubMed ID: 16797163
[TBL] [Abstract][Full Text] [Related]
14. N-acetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: a clinical study of the new vision-saving drug N-acetylcarnosine eyedrop therapy in a database population of over 50,500 patients.
Babizhayev MA; Micans P; Guiotto A; Kasus-Jacobi A
Am J Ther; 2009; 16(6):517-33. PubMed ID: 19487926
[TBL] [Abstract][Full Text] [Related]
15. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.
Smith RC; Jin H; Li C; Bark N; Shekhar A; Dwivedi S; Mortiere C; Lohr J; Hu Q; Davis JM
Schizophr Res; 2013 Jan; 143(1):18-24. PubMed ID: 23200554
[TBL] [Abstract][Full Text] [Related]
16. Cognitive impairments and psychopathological parameters in patients of the schizophrenic spectrum.
Kontaxaki MI; Kattoulas E; Smyrnis N; Stefanis NC
Psychiatriki; 2014; 25(1):27-38. PubMed ID: 24739500
[TBL] [Abstract][Full Text] [Related]
17. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
Liu F; Guo X; Wu R; Ou J; Zheng Y; Zhang B; Xie L; Zhang L; Yang L; Yang S; Yang J; Ruan Y; Zeng Y; Xu X; Zhao J
Schizophr Res; 2014 Mar; 153(1-3):169-76. PubMed ID: 24503176
[TBL] [Abstract][Full Text] [Related]
18. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
Lee SW; Lee JG; Lee BJ; Kim YH
Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
[TBL] [Abstract][Full Text] [Related]
19. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
Lindenmayer JP; Khan A
Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275
[TBL] [Abstract][Full Text] [Related]
20. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
Javitt DC; Buchanan RW; Keefe RS; Kern R; McMahon RP; Green MF; Lieberman J; Goff DC; Csernansky JG; McEvoy JP; Jarskog F; Seidman LJ; Gold JM; Kimhy D; Nolan KS; Barch DS; Ball MP; Robinson J; Marder SR
Schizophr Res; 2012 Apr; 136(1-3):25-31. PubMed ID: 22169248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
